- Home
- ZGN vs BLTE Comparison
ZGN vs BLTE Comparison
Compare ZGN & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- BLTE
- Stock Information
- Founded
- ZGN 1910
- BLTE 2018
- Country
- ZGN Italy
- BLTE United States
- Employees
- ZGN N/A
- BLTE N/A
- Industry
- ZGN Apparel
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- ZGN Consumer Discretionary
- BLTE Health Care
- Exchange
- ZGN Nasdaq
- BLTE Nasdaq
- Market Cap
- ZGN 1.9B
- BLTE 2.1B
- IPO Year
- ZGN N/A
- BLTE 2022
- Fundamental
- Price
- ZGN $6.46
- BLTE $55.67
- Analyst Decision
- ZGN Buy
- BLTE Strong Buy
- Analyst Count
- ZGN 2
- BLTE 4
- Target Price
- ZGN $8.05
- BLTE $96.67
- AVG Volume (30 Days)
- ZGN 1.0M
- BLTE 41.0K
- Earning Date
- ZGN 03-27-2025
- BLTE 05-12-2025
- Dividend Yield
- ZGN 1.99%
- BLTE N/A
- EPS Growth
- ZGN N/A
- BLTE N/A
- EPS
- ZGN 0.31
- BLTE N/A
- Revenue
- ZGN $2,015,371,157.00
- BLTE N/A
- Revenue This Year
- ZGN $3.72
- BLTE N/A
- Revenue Next Year
- ZGN $5.99
- BLTE N/A
- P/E Ratio
- ZGN $20.86
- BLTE N/A
- Revenue Growth
- ZGN 2.21
- BLTE N/A
- 52 Week Low
- ZGN $6.13
- BLTE $31.01
- 52 Week High
- ZGN $13.36
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- ZGN 29.54
- BLTE 26.06
- Support Level
- ZGN $6.13
- BLTE $64.18
- Resistance Level
- ZGN $8.10
- BLTE $65.85
- Average True Range (ATR)
- ZGN 0.36
- BLTE 2.44
- MACD
- ZGN -0.06
- BLTE -1.61
- Stochastic Oscillator
- ZGN 13.45
- BLTE 0.00
Stock Price Comparison Chart: ZGN vs BLTE
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.